Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Brainstorm Cell Therapeutics Inc. (BCLI) had Return on Tangible Equity of 33.24% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-3.85M |
|
-- |
|
-- |
|
$3.61M |
|
$-3.61M |
|
$-0.24M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.85M |
|
$-3.61M |
|
$-3.57M |
|
11.04M |
|
11.04M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$0.32M |
|
$0.15M |
|
$0.47M |
|
$0.79M |
|
$12.38M |
|
-- |
|
-- |
|
$12.38M |
|
$-11.60M |
|
$-11.60M |
|
$-11.60M |
|
11.04M |
|
| Cash Flow Statement Financials | |
$-2.21M |
|
$0.00M |
|
$2.15M |
|
$0.28M |
|
$0.21M |
|
$-0.07M |
|
$2.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.03 |
|
-- |
|
-- |
|
-- |
|
-0.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.21M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
33.24% |
|
|
Return on Tangible Equity |
33.24% |
-489.21% |
|
33.24% |
|
$-1.05 |
|
$-0.20 |
|
$-0.20 |
|